{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:59:21Z","timestamp":1784300361406,"version":"3.55.0"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2011,8,12]],"date-time":"2011-08-12T00:00:00Z","timestamp":1313107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The advent of liquid chromatography\u2010tandem mass spectrometry (LC\u2010MS\/MS), with the sensitivity it confers, permits the analysis of both phase I and II drug metabolites that in the past would have been difficult to target using other techniques. These metabolites may have relevance to current analytical toxicology employing LC\u2010MS\/MS, and lorazepam was chosen as a model drug for investigation, as only the parent compound has been targeted for screening purposes. Following lorazepam administration (2 mg, p.o.) to 6 volunteers, metabolites were identified in urine by electrospray ionization LC\u2010MS\/MS, aided by the use of deuterated analogues generated by microsomal incubation for use as internal chromatographic and mass spectrometric markers. Metabolites present were lorazepam glucuronide, a quinazolinone, a quinazoline carboxylic acid, and two hydroxylorazepam isomers, one of which is novel, having the hydroxyl group located on the fused chlorobenzene ring. The quinazolinone, and particularly the quinazoline carboxylic acid metabolite, provided longer detection windows than lorazepam in urine extracts not subjected to enzymatic hydrolysis, a finding that is highly relevant to toxicology laboratories that omit hydrolysis in order to rapidly reduce the time spent on gas chromatography\u2010mass spectrometry (GC\u2010MS) analysis. With hydrolysis, the longest windows of detection were achieved by monitoring lorazepam, supporting the targeting of the aglycone with free drug for those incorporating hydrolysis in their analytical toxicology procedures. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dta.305","type":"journal-article","created":{"date-parts":[[2011,8,12]],"date-time":"2011-08-12T06:36:25Z","timestamp":1313130985000},"page":"695-704","source":"Crossref","is-referenced-by-count":5,"title":["Metabolites of lorazepam: Relevance of past findings to present day use of LC\u2010MS\/MS in analytical toxicology"],"prefix":"10.1002","volume":"3","author":[{"given":"Sophie C.","family":"Turfus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin A","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Kicman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,12]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600660119"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(04)00642-7"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.897"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.559"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx0501637"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00231a018"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/bms.1200180607"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.026328"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174511"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2004.04.027"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","unstructured":"A.Negrusz Estimate of the incidence of drug\u2010facilitated sexual assault in the United States atFBI Laboratory Symposium on Forensic Toxicology Washington DC 2004.","DOI":"10.1037\/e513312006-001"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-003-1896-z"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcfm.2005.03.009"},{"key":"e_1_2_7_15_2","first-page":"1059","article-title":"Urinary metabolites of 7\u2010chloro\u20105\u2010(ortho\u2010chlorophenyl)\u20101,3\u2010dihydro\u20103\u2010hydroxy\u20102H\u20101,4\u2010benzodiazepin\u20102\u2010one (lorazepam) in humans and 4 animal species","volume":"21","author":"Schillings R.T.","year":"1971","journal-title":"Arzneimittel\u2010Forschung"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976203329"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/48.10.1017"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/20.6.416"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199812000-00016"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/22.4.270"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.200500268"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.07.014"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/30.8.524"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/32.7.491"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2005.07.033"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.065631"},{"key":"e_1_2_7_27_2","unstructured":"Guidance for Industry\u2014Bioanalytical Method Validation (2001).Available at:www.fda.gov\/downloads\/Drugs\/GuidanceCompliance RegulatoryInformation\/Guidances\/UCM070107.pdf[February 2011]."},{"key":"e_1_2_7_28_2","unstructured":"SOFT\/AAFS Forensic Toxicology Laboratory Guidelines 2006 version. Available at:http:\/\/www.soft\u2010tox.org\/docs\/Guidelines%202006%20Final.pdf[February 2011]."},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.05.010"},{"key":"e_1_2_7_30_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0090-9556(25)00105-9","article-title":"Diastereoisomeric glucuronides of oxazepam. Isolation and stereoselective enzymic hydrolysis","volume":"7","author":"Ruelius H.W.","year":"1979","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/18.4.185"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00419-4"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/elps.1150150111"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/25.2.137"},{"key":"e_1_2_7_35_2","unstructured":"SPE Reference Manual and Users Guide Phenomenex."},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01974986"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00198307"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.101"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/chir.530050302"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01944753"},{"key":"e_1_2_7_41_2","first-page":"1055","article-title":"Disposition of 7\u2010chloro\u20105\u2010(o\u2010chlorophenyl)\u20101,3\u2010dihydro\u20103\u2010hydroxy\u20102H\u20101,4\u2010benzodiazepin\u20102\u2010o ne (lorazepam) in humans. Determination of the drug by electron capture gas chromatography","volume":"21","author":"Knowles J.A.","year":"1971","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2009.04.005"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.305","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:43:00Z","timestamp":1760395380000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,12]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1002\/dta.305"],"URL":"https:\/\/doi.org\/10.1002\/dta.305","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,12]]}}}